Skip to main content

Day: April 9, 2024

Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024

Poster outlines the parameters for developing a flow-cytometry-based PPMP as a companion diagnostic to predict volasertib responders, based on a proof-of-concept study using 41 primary acute myeloid leukemia (AML) samples Plans to incorporate a dose optimization prelude to enhance patient response and tolerability also outlined in the posterFOSTER CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) — Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer therapies identified by its Predictive Precision Medicine Platform (PPMP), today presented the design for the PPMP-enabled Phase 2 trial with volasertib, in combination with decitabine, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) at the American Association for Cancer...

Continue reading

Jianzhi Education Technology Group Company Limited Reports Fiscal Year 2023 Financial Results

BEIJING, April 09, 2024 (GLOBE NEWSWIRE) — Jianzhi Education Technology Group Company Limited (the “Company” or “Jianzhi”) (NASDAQ: JZ), a leading provider of digital educational content in China, today announced its financial results for fiscal year ended December 31, 2023.Net revenues were 440.5 million (US$62.0 million) for fiscal year 2023, compared to RMB505.7 million during the same period in 2022. Gross profit was RMB16.2 million (US$2.3 million) for fiscal year 2023, and a gross loss of RMB5.5 million for the same period in 2022. Net loss for 2023 was RMB382.8 million (US$53.9 million), compared to net loss of RMB196.6 million during the same period in 2022.The following table sets forth a summary of the consolidated results of operations for the years indicated:    For the Years Ended December 31,        2022 2023        RMB  RMB  US$    ...

Continue reading

Brookfield Corporation to Host First Quarter 2024 Results Conference Call

BROOKFIELD, NEWS, April 09, 2024 (GLOBE NEWSWIRE) — Brookfield Corporation (TSX: BN, NYSE: BN) will host its first quarter 2024 conference call and webcast on Thursday, May 9, 2024 at 10:00 a.m. (ET). Results will be released that morning before 7:00 a.m. (ET) and will be available on our website at https://bn.brookfield.com/news-events/press-releases. Participants can join by conference call or webcast: Conference CallPlease pre-register by conference call: https://register.vevent.com/register/BI004b533cfc974dc2b6b521b32900f76d Upon registering, you will be emailed a dial-in number, and unique PIN. This process will bypass the operator and avoid the queue.WebcastPlease join and register by webcast:  https://edge.media-server.com/mmc/p/m49bqp6n Replay of the event is available on the above webcast link for 90 days.About...

Continue reading

APA Corporation Announces Updates to Executive Leadership

HOUSTON, April 09, 2024 (GLOBE NEWSWIRE) — APA Corporation (Nasdaq: APA) has announced updates to its executive leadership team to coincide with a restructuring of its development function and the integration of the recently closed acquisition of Callon Petroleum. The changes are effective immediately. “Building on the momentum of our recently closed acquisition, we are updating our leadership structure to better align with the evolving needs of our business,” said John J. Christmann, APA chief executive officer. “Today’s changes will help advance important priorities of the APA strategy and create opportunities for continued leadership development within our organization.” Steve Riney, president and chief financial officer, will now oversee asset development functions, including the asset teams, Planning and Land in addition to...

Continue reading

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class CDK9 inhibitor, PRT2527, in Phase 1 development, is highly effective in preclinical hematological models as monotherapy and provides improved depth and duration of response in combination with BTK/BCL2 inhibition Next Generation CDK4/6 Inhibitor, PRT3645, is highly effective in combination with other targeted therapies in preclinical models of breast cancer, CRC and NSCLC WILMINGTON, Del., April 09, 2024 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the presentation of new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting...

Continue reading

Applied Digital Reschedules Fiscal Third Quarter 2024 Earnings Conference Call to Thursday, April 11, 2024 at 5:00 p.m. Eastern Time

DALLAS, April 09, 2024 (GLOBE NEWSWIRE) — Applied Digital Corporation (Nasdaq: APLD) (“Applied Digital” or the “Company”), a designer, builder and operator of next-generation digital infrastructure designed for High-Performance Computing (“HPC”) applications, today announced that, in light of a scheduling issue, has moved its fiscal third quarter 2024 earnings conference call to Thursday, April 11, 2024, at 5:00 p.m. Eastern time. Financial and operational results for the fiscal third quarter ended February 29, 2024, will be issued after the market closes on Thursday, April 11, 2024. Applied Digital management will provide prepared remarks, followed by a question-and-answer period. Date: Thursday, April 11, 2024Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific time)U.S. dial-in number: 1-877-407-0792International...

Continue reading

Vicor Corporation to Hold First Quarter Earnings Conference Call and Webcast on April 23, 2024

ANDOVER, Mass., April 09, 2024 (GLOBE NEWSWIRE) — Vicor Corporation (NASDAQ: VICR) announced today it will hold its first quarter 2024 earnings conference call and webcast on Tuesday, April 23, 2024 at 5:00 p.m. (Eastern). Prepared remarks regarding the company’s financial and operational results for the three months ended March 31, 2024 will be followed by a question and answer period with Patrizio Vinciarelli, Chief Executive Officer, Jim Schmidt, Chief Financial Officer, and Phil Davies, Corporate Vice President, Global Sales and Marketing. Results for the first quarter will be released over GlobeNewswire at the close of the NASDAQ Market Session on April 23, 2024, and the press release and a summary of the company’s financial statements will be available shortly thereafter on the Investor Relations page of Vicor’s...

Continue reading

NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results

CARMEL, Ind., April 09, 2024 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter and fiscal year 2023 for the period ended December 31, 2023. Recent Operational HighlightsExpanded total covered lives to approximately 16 million individuals, an increase of 300% compared to 4 million individuals as of April 1, 2023. Recent medical policy coverages include:BCBS plan in the mid-Atlantic region, providing coverage for approximately 7 million covered lives. Coverage from a major insurer covering approximately 1 million covered lives. BCBS plan in the mid-Atlantic with approximately 3.5 million covered lives.The company...

Continue reading

Omega Flex, Inc. Announces Election of a Director: Stephen M. Shea

EXTON, Pa., April 09, 2024 (GLOBE NEWSWIRE) — Omega Flex, Inc. (the “Company”) (NASDAQ: OFLX) today announces that that our board of directors elected Stephen M. Shea as a director. Mr. Shea has been designated as a Class 2 director, and he will have a term expiring at the 2025 annual shareholder meeting. He will serve on our Audit committee. Mr. Shea is currently the Executive Vice President and Chief Financial Officer of Mestek, Inc., the Company’s former parent corporation. He served as Mestek, Inc.’s principal financial and accounting officer prior to its going private transaction in 2006 and has over 30 years’ experience in the HVAC manufacturing industry. Mr. Shea was formerly a Certified Public Accountant with the Hartford, Connecticut accounting firm of Spitz, Sullivan, Wachtel & Falcetta, and he has a Master’s Degree...

Continue reading

Australian Oilseeds, Largest APAC Producer of Non-Chemical, Non- GMO “Cold-Processing” Vegetable Oil, Expands Australian Operations to the United States

~ Over the past 20 years, AOI has grown to be the largest cold pressing oil plant in the APAC region, pressing strictly GMO free conventional and organic oilseeds ~ New York, NY and Sydney, Australia, April 09, 2024 (GLOBE NEWSWIRE) — Australian Oilseeds Holdings Limited (Nasdaq: COOT), a Cayman Islands exempted company “Australian Oilseeds” or “AOI”) is pleased to announce that it will be expanding its Australian operations to the United States effective July 2024. A pioneer in regenerative farming methods, AOI will, through its subsidiary company, Good Earth Oils, distribute Australian cold pressed NON-GMO canola oil and olive oil to retail and wholesalers in the United States. AOI and Good Earth Oils purchase its NON-GMO canola seeds and olive oil from farmers who are reducing their use of chemicals in their farming systems....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.